You are here: Industry Insights > Novartis

News List

Novartis' Sandoz chief exits with 'de-integration' undone. Could a spinoff be next? fiercepharma
March 15, 2019
Novartis CEO Vas Narasimhan said in January that his company is focused on the “de-integration” of Sandoz from the rest of its operations.
Novartis chairman says drugmaker has no plans to offload Sandoz unit firstwordpharma
March 06, 2019
According to an interview published Monday in the Finanz und Wirtschaft newspaper, Novartis chairman Joerg Reinhardt indicated that the company does not intend to divest its Sandoz generics business, nor any parts of it.
Novartis' shift to superpricey cell and gene therapies draws investor ire fiercepharma
March 03, 2019
It's not unusual for critics to challenge top drugmakers for price hikes on old drugs, but Novartis is contending with a different kind of pricing pressure from a Swiss shareholder activist group.
Blackstone, Novartis found cardiovascular startup with $250M fiercebiotech
February 28, 2019
Blackstone Life Sciences has committed $250 million to create a cardiovascular startup with Novartis. The biotech, Anthos Therapeutics....
Novartis exercises rights to Ionis’ CV drug TQJ230 pharmaceutical-technology
February 26, 2019
Swiss pharmaceutical giant Novartis has announced it has exercised the option to license its right to develop and commercialise TQJ230, a targeted cardiovascular (CV) therapy....
Novartis chief’s 2018 take-home pay suffers—not from Cohen but from low-grade returns fiercepharma
February 24, 2019
Novartis CEO Vas Narasimhan navigated through a tough and transitional year at the drugmaker, racking up almost $10 million in salary, incentive pay and equity awards for his efforts. But his 2018 take-home pay took a hit on longer-term shareholder return
Novartis’ AveXis doubles down with $115M manufacturing investment fiercepharma
February 24, 2019
As an FDA action date quickly approaches for a gene therapy that Novartis snatched up last year, the biotech that is developing the treatment says it needs to more than double the size of its new manufacturing operations. AveXis now plans to have 400 empl
ICER finds Novartis' gene therapy Zolgensma cost effective up to $900 000 based on commonly used threshold; Biogen, Ionis' Spinraza would need firstwordpharma
February 23, 2019
Using an alternate measure of life years (LY) gained at the threshold between $100 000 and $150 000, ICER found that Zolgensma would be cost-effective between $710 000 and $1.5 million.
Novartis receives FDA approval for Egaten biospectrumasia
February 21, 2019
Egaten is currently the only medicine for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines
Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease worldpharmanews
February 19, 2019
Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page